AAAAAA

   
Results: 1-8 |
Results: 8
MODULATION AND PREVENTION OF MULTIDRUG-RESISTANCE BY INHIBITORS OF P-GLYCOPROTEIN
Authors: SIKIC BI FISHER GA LUM BL HALSEY J BEKETICORESKOVIC L CHEN G
Citation: Bi. Sikic et al., MODULATION AND PREVENTION OF MULTIDRUG-RESISTANCE BY INHIBITORS OF P-GLYCOPROTEIN, Cancer chemotherapy and pharmacology, 40, 1997, pp. 13-19
CLINICAL-SIGNIFICANCE OF BLAST CELL KARYOTYPE CHANGE AT RELAPSE OF CHILDHOOD ALL
Authors: VORA A HALSEY J HOLT S EDEN T RICHARDS S
Citation: A. Vora et al., CLINICAL-SIGNIFICANCE OF BLAST CELL KARYOTYPE CHANGE AT RELAPSE OF CHILDHOOD ALL, Blood, 88(10), 1996, pp. 1794-1794
THE EFFECT OF GLUCOCORTICOIDS ON JOINT DESTRUCTION IN RHEUMATOID-ARTHRITIS
Authors: KIRWAN JR BYRON M DIEPPE P EASTMOND C HALSEY J HICKLING P HOLLINGWORTH P JACOBY R KIRK A MORAN C REID D SWANNELL T YATES D COOPER C GEORGE E FORBES D JESSOP J WATT I
Citation: Jr. Kirwan et al., THE EFFECT OF GLUCOCORTICOIDS ON JOINT DESTRUCTION IN RHEUMATOID-ARTHRITIS, The New England journal of medicine, 333(3), 1995, pp. 142-146
THE EFFECT OF SDZ-PSC-833, A CYCLOSPORINE-D ANALOG, ON THE PHARMACOKINETIC BEHAVIOR OF ETOPOSIDE (E) DURING A PHASE-I TRIAL TO MODULATE MULTIDRUG-RESISTANCE
Authors: LUM BL FISHER GA HAUSDORF J GOTTWALD M COLLINS H BROPHY NA EHSAN MN HALSEY J SIKIC BI
Citation: Bl. Lum et al., THE EFFECT OF SDZ-PSC-833, A CYCLOSPORINE-D ANALOG, ON THE PHARMACOKINETIC BEHAVIOR OF ETOPOSIDE (E) DURING A PHASE-I TRIAL TO MODULATE MULTIDRUG-RESISTANCE, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 175-175
ANALYSIS OF MOLECULAR BREAKPOINT AND M-RNA TRANSCRIPTS IN A PROSPECTIVE RANDOMIZED TRIAL OF INTERFERON IN CHRONIC MYELOID-LEUKEMIA - NO CORRELATION WITH CLINICAL-FEATURES, CYTOGENETIC RESPONSE, DURATION OF CHRONIC PHASE, OR SURVIVAL
Authors: SHEPHERD P SUFFOLK R HALSEY J ALLAN N
Citation: P. Shepherd et al., ANALYSIS OF MOLECULAR BREAKPOINT AND M-RNA TRANSCRIPTS IN A PROSPECTIVE RANDOMIZED TRIAL OF INTERFERON IN CHRONIC MYELOID-LEUKEMIA - NO CORRELATION WITH CLINICAL-FEATURES, CYTOGENETIC RESPONSE, DURATION OF CHRONIC PHASE, OR SURVIVAL, British Journal of Haematology, 89(3), 1995, pp. 546-554
PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE
Authors: BARTLETT NL LUM BL FISHER GA BROPHY NA EHSAN MN HALSEY J SIKIC BI
Citation: Nl. Bartlett et al., PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE, Journal of clinical oncology, 12(4), 1994, pp. 835-842
PHARMACODYNAMICS (PD) OF DOXORUBICIN (DOX) WITH CYCLOSPORINE (CSA) ASA MODULATOR OF DRUG-RESISTANCE
Authors: LUM BL BARTLETT NL FISHER GA BROPHY NA EHSAN M HALSEY J SIKIC BI
Citation: Bl. Lum et al., PHARMACODYNAMICS (PD) OF DOXORUBICIN (DOX) WITH CYCLOSPORINE (CSA) ASA MODULATOR OF DRUG-RESISTANCE, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 210-210
CLINICAL-TRIALS OF MODULATION OF MULTIDRUG-RESISTANCE - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS
Authors: LUM BL FISHER GA BROPHY NA YAHANDA AM ADLER KM KAUBISCH S HALSEY J SIKIC BI
Citation: Bl. Lum et al., CLINICAL-TRIALS OF MODULATION OF MULTIDRUG-RESISTANCE - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS, Cancer, 72(11), 1993, pp. 3502-3514
Risultati: 1-8 |